Browse

Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination

DC Field Value Language
dc.contributor.authorJeong, Chang Wook-
dc.contributor.authorLim, Dae Jung-
dc.contributor.authorSon, Hwancheol-
dc.contributor.authorLee, Sang Eun-
dc.contributor.authorJeong, Hyeon-
dc.date.accessioned2010-06-28T23:12:28Z-
dc.date.available2010-06-28T23:12:28Z-
dc.date.issued2008-03-26-
dc.identifier.citationUrol Int. 2008;80(2):157-161en
dc.identifier.issn1423-0399 (Electronic)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18362485-
dc.identifier.urihttp://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000112606&Ausgabe=234231&ProduktNr=224282&filename=000112606.pdf-
dc.identifier.urihttp://hdl.handle.net/10371/67950-
dc.description.abstractINTRODUCTION: We performed a prospective, randomized study to examine the efficacies of levofloxacin and doxazosin alone and as a combination therapy in patients with National Institutes of Health (NIH) category III chronic prostatitis/chronic pelvic pain syndrome. PATIENTS AND METHODS: Men with a NIH diagnosis of category III chronic prostatitis/chronic pelvic pain syndrome and who had experienced pelvic pain for more than 3 months during the last 6 months were enrolled. All patients underwent treatment for 6 weeks. The patients were assessed at baseline and after 2 and 6 weeks by using the NIH Chronic Prostatitis Symptom Index. Eighty-one men (average age 40.1 years) were randomized to either the levofloxacin group (n = 26), the doxazosin group (n = 26), or the combination group (n = 29). RESULTS: The average baseline NIH Chronic Prostatitis Symptom Index total scores were 22.6, 22.4, and 24.1, respectively. At 6 weeks, the total scores were 11.2 (response rate 50.3%), 17.7 (response rate 21.1%), and 13.1 (response rate 45.6%), respectively. The levofloxacin group showed a higher response rate than the doxazosin group, not at 2 weeks but at 6 weeks (p < 0.001). CONCLUSIONS: For a 6-week short-term treatment levofloxacin is more effective than doxazosin for chronic prostatitis/chronic pelvic pain syndrome. In addition, levofloxacin monotherapy was also more effective when compared with the combination therapy.en
dc.language.isoenen
dc.publisherKargeren
dc.subjectAdrenergic alpha-Antagonists/*therapeutic useen
dc.subjectAdulten
dc.subjectAnti-Bacterial Agents/*therapeutic useen
dc.subjectDoxazosin/*therapeutic useen
dc.subjectDrug Therapy, Combinationen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOfloxacin/*therapeutic useen
dc.subjectProspective Studiesen
dc.subjectProstatitis/*drug therapyen
dc.titleTreatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combinationen
dc.typeArticleen
dc.contributor.AlternativeAuthor정창욱-
dc.contributor.AlternativeAuthor임대정-
dc.contributor.AlternativeAuthor손환철-
dc.contributor.AlternativeAuthor이상은-
dc.contributor.AlternativeAuthor정현-
dc.identifier.doi10.1159/000112606-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse